BTK and B-cell chronic lymphocytic leukemia: While high levels of peripheral blood BTK occupancy are seen with several agents, zanubrutinib’s high plasma levels may enable penetration into lymph nodes and other niches (i.e., bone marrow) which could account for the improved efficacy of zanubrutinib over ibrutinib in randomized phase 3 studies in CLL and WM.